Eton Pharmaceuticals Inc (NAS:ETON)

Q3 2025 Eton Pharmaceuticals Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: $19.14 (-0.57%)

Transcript 10-Q8-K

Key Points

Positve

Eton Pharmaceuticals Inc (ETON) reported a record quarter with triple-digit year-over-year revenue growth, marking the 19th consecutive quarter of sequential product revenue growth.
The company generated $12 million of cash from operations in the quarter, demonstrating strong cash flow management.
Eton Pharmaceuticals Inc (ETON) successfully reduced adjusted SG&A expenses sequentially from the second quarter to the third quarter, indicating effective cost control.
The company has made significant progress with its development activities, which are expected to drive future revenue and earnings growth.
Eton Pharmaceuticals Inc (ETON) has a strong pipeline with upcoming milestones, including the expected launch of ET 600 and the submission of a revised formulation of Kindivi.

Negative

The net active patient count for Increlex remained relatively flat due to a higher number of patients aging out and discontinuing treatment.
The company experienced a less favorable payer mix for Increlex in the third quarter, resulting in lower revenue per patient compared to the second quarter.
Adjusted gross margin was negatively impacted by Increlex XS-related costs, including the transition of XS distribution and the supply agreement with Esteve.
General and administrative expenses increased compared to the prior year period due to higher product advertising, launch year promotional expenses, and increased compensation costs.
The current label restriction on Kindivi has weighed on its adoption, as the largest unmet need is among young children under 5 years old.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ETON.OQ - Eton Pharmaceuticals Inc
Q3 2025 Eton Pharmaceuticals Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to the Eaton Pharmaceuticals 3rd quarter 2025 financial results conference call. At this time, all participants are in listen-only mode. Following the formal remarks, we will open the call up for your questions.

Please be advised that this call is being recorded at the company's request.

At this time I'd like to turn it over to David Krimpa, Chief Business Officer at Eaton Pharmaceuticals. Please proceed.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you operator. Good afternoon everyone and welcome to Eaton's 3rd

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.